Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas A Hombach

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Immunotherapy|July 9, 2013
Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancerAndreas A Hombach, Hinrich Abken
Oncoimmunology|June 27, 2013
Targeting two co-operating cytokines efficiently shapes immune responsesAndreas A Hombach, Hinrich Abken
Frontiers in Immunology|June 14, 2013
Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the BattleAndreas A Hombach, Hinrich Abken
Expert Review of Clinical Immunology|August 23, 2016
Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?Andreas A Hombach, Hinrich Abken
International Journal of Cancer|October 28, 2011
Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signallingAndreas A Hombach, Hinrich Abken
Methods in Molecular Biology (Clifton, N.J.)|August 22, 2012
Antibody-IL2 fusion proteins for tumor targetingAndreas A Hombach, Hinrich Abken
Cancers|August 30, 2017
Most Do, but Some Do Not: CD4⁺CD25<sup>-</sup> T Cells, but Not CD4⁺CD25⁺ Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)Andreas A Hombach, Hinrich Abken
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 24, 2019
Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30<sup>-</sup> TumorsAndreas A Hombach, Gunter Rappl, Hinrich Abken
Frontiers in Immunology|November 26, 2013
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T CellsMarkus Chmielewski, Andreas A Hombach, Hinrich Abken
Immunological Reviews|December 17, 2013
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stromaMarkus Chmielewski, Andreas A Hombach, Hinrich Abken
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Immunotherapy|July 9, 2013
Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancerAndreas A Hombach, Hinrich Abken
Oncoimmunology|June 27, 2013
Targeting two co-operating cytokines efficiently shapes immune responsesAndreas A Hombach, Hinrich Abken
Frontiers in Immunology|June 14, 2013
Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the BattleAndreas A Hombach, Hinrich Abken
Expert Review of Clinical Immunology|August 23, 2016
Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?Andreas A Hombach, Hinrich Abken
International Journal of Cancer|October 28, 2011
Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signallingAndreas A Hombach, Hinrich Abken
Methods in Molecular Biology (Clifton, N.J.)|August 22, 2012
Antibody-IL2 fusion proteins for tumor targetingAndreas A Hombach, Hinrich Abken
Cancers|August 30, 2017
Most Do, but Some Do Not: CD4⁺CD25<sup>-</sup> T Cells, but Not CD4⁺CD25⁺ Treg Cells, Are Cytolytic When Redirected by a Chimeric Antigen Receptor (CAR)Andreas A Hombach, Hinrich Abken
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 24, 2019
Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30<sup>-</sup> TumorsAndreas A Hombach, Gunter Rappl, Hinrich Abken
Frontiers in Immunology|November 26, 2013
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T CellsMarkus Chmielewski, Andreas A Hombach, Hinrich Abken
Immunological Reviews|December 17, 2013
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stromaMarkus Chmielewski, Andreas A Hombach, Hinrich Abken
Pageof 4